Form 4: Monte Rosa CEO Sells GLUE Shares Under 10b5-1 Plan

Monte Rosa Therapeutics CEO Markus Warmuth sold 5,466 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Markus Warmuth, President & CEO and Director of Monte Rosa Therapeutics, Inc. (GLUE), reported the sale of common stock.
• The transactions occurred on January 7, 2026.
• A total of 5,466 shares of common stock were sold across three separate transactions.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Weighted average sale prices were $23.2422, $23.8762, and $24.5736.
• Following these transactions, Warmuth beneficially owns 618,937 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of a pre-planned insider stock sale under a Rule 10b5-1 plan, which typically does not imply new information or a change in company outlook.

Negatives

• Insider selling, even under a pre-arranged plan, can sometimes be interpreted by the market as a lack of confidence, though the 10b5-1 plan mitigates this perception.

Risks

• No specific risks were detailed in this Form 4 filing, which is solely for reporting insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction report does not provide specific industry context, but insider sales are a routine disclosure for publicly traded companies, particularly when executed under pre-arranged 10b5-1 plans.

Stakeholder Impact

• Shareholders: May observe a reduction in the CEO's direct holdings, though the pre-planned nature of the sale under Rule 10b5-1 typically mitigates concerns about management's confidence in the company's future.

Key Dates

Keywords

Monte Rosa Therapeutics, GLUE, Markus Warmuth, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director